The current study demonstrates that CIT significantly improved OS and PFS compared to SEQ among the 1–49% PD-L1 expression subgroup, which agrees with previous phase III trials [14,15,16,17] and the cancer-immune set point hypothesis of converting the immune-desert phenotype into an immune-inflamed phenotype by activating the priming phase with chemotherapy [28]. Here, CD274 is linked to cancer.